New for 2020, The Cell-Based Immunotherapy stream focuses on the latest protein engineering, clinical and analytical strategies driving the development of cell-based immunotherapies such as CAR Ts, TCRs, TILs and NKs, for the treatment of cancer and immune
disorders. Topics include improving target identification, optimizing product design, specificity, safety, characterization and analytics.
Conferences Include:
August 31 - September 1
Improving Immunotherapy Efficacy and Safety
September 2-3
CAR Ts, TCRs and TILs
September 3-4
Cell and Gene Therapy Analytics
Keynote Speakers:
Prasad Adusumilli, MD, FACS, FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma
Adrian Bot, PhD, Vice President, Translational Medicine, Kite Pharma, a Gilead Company
Jan Joseph (Jos) Melenhorst, PhD Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania
Jeffrey Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation,
University of Minnesota